ESAIY Eisai Co., Ltd. Unsponsored ADR Loading...

From BIIB earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
13:30
Feb 06 ◎
Robin Kramer Chief Financial Officer, Biogen Inc. BIIB Q4 FY25 call
Eisai's Lecanemab sales continue to grow strongly, reinforcing the partnership and commercial momentum.
ESAIY
HIGH

About ESAIY Analyst Coverage

Buzzberg tracks ESAIY (Eisai Co., Ltd. Unsponsored ADR) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Robin Kramer.